The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells

Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL

(2012) Bodvael Pennarun et al.   JOURNAL OF PATHOLOGY

Are we ready to recommend aspirin for cancer prevention?

(2012) Andrew T Chan et al.   LANCET

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials

(2012) Peter M Rothwell et al.   LANCET

Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials

(2012) Peter M Rothwell et al.   LANCET

Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials

(2012) Annemijn M Algra et al.   LANCET ONCOLOGY

Priming effect of aspirin for tumor cells to augment cytotoxic action of cisplatin against tumor cells: implication of altered constitution of tumor microenvironment, expression of cell cycle, apoptosis, and survival regulatory molecules

(2012) Anjani Kumar et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

The role of aspirin in cancer prevention

(2012) Michael J. Thun et al.   Nature Reviews Clinical Oncology

Will an Aspirin a Day Keep Cancer Away?

(2012) J. Kaiser   SCIENCE

Pt(IV) complexes as prodrugs for cisplatin

(2011) Yi Shi et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials

(2010) Peter M Rothwell et al.   LANCET

Aspirin for the Chemoprevention of Colorectal Adenomas: Meta-analysis of the Randomized Trials

(2009) Bernard F. Cole et al.   JNCI-Journal of the National Cancer Institute

Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue

(2008) H. Choy et al.   CLINICAL CANCER RESEARCH